Production (Stage)
BioVaxys Technology Corp.
BVAXF
$0.0229
$0.00031.33%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.31M | 2.81M | 2.29M | 1.83M | 1.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.34M | 2.84M | 2.29M | 1.81M | 1.48M |
| Operating Income | -3.34M | -2.84M | -2.29M | -1.81M | -1.48M |
| Income Before Tax | -4.56M | -4.03M | -2.89M | -2.66M | -3.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.56 | -4.03 | -2.89 | -2.66 | -3.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.56M | -4.03M | -2.89M | -2.66M | -3.91M |
| EBIT | -3.34M | -2.84M | -2.29M | -1.81M | -1.48M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 1.01B | 933.12M | 816.15M | 718.82M | 645.56M |
| Average Diluted Shares Outstanding | 1.01B | 933.12M | 816.15M | 718.82M | 645.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |